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Natural  marine  products  can help  increase  the  quality  of life  in  patients  with  neurological  diseases.  A
large number  of  marine  products  act  against  Alzheimer’s  disease  through  varying  pathways.  Accord-
ing  to structure-  and  ligand-based  analyses,  caulerpin,  an  alkaloid  primarily  isolated  from  the  genus
Caulerpa,  possesses  activity  against  monoamine  oxidase  B. To  predict  the  activity  of  caulerpin,  we
employed  Volsurf  descriptors  and  the  machine  learning  Random  Forest  algorithm  in parallel  with  a
structure-based  methodology  that  included  molecular  docking.  Using  caulerpin  as  a lead compound,
a  database  containing  108 analogs  was  evaluated,  and nine  were  selected  as  active. The  structuresolecular docking
onoamine oxidase B
irtual screening
selected  as  active  exhibited  polar  and non-polar  substitutions  on the  caulerpin  skeleton,  which  were
relevant  for  their  activity.  Dragon  consensus  drug-like  scoring  was  applied  to identify  the  active  analogs
that  might  serve  as  good  drug  candidates,  and  the  entire  group  presented  satisfactory  performance.
These  results  indicate  the possibility  of  using  these  analogs  as  potential  leads  against  Alzheimer’s
disease.
©  2015  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
Alzheimer’s disease (AD) has emerged as the most prevalent
ype of late-life disorder in humans, afﬂicting 45% of people over
5 years old (Liu et al., 2013). This burden is increasing as the elderly
opulation continues to grow. In general, AD is associated with
euronal loss, synaptic dysfunction and functional abnormalities
f mitochondrial structures (LaFerla and Oddo, 2005). In the litera-
ure, different methods of controlling AD have been reported, which
ffer alternative mechanisms of action (Tian et al., 2014; Riediger
t al., 2009). In an attempt to improve the quality of life for AD
atients, numerous studies are being conducted to develop more
fﬁcient drugs.The marine environment covers 70% of the earth’s surface and
rovides a fascinating variety of biodiversity that exceeds that
f the terrestrial environment. The biodiversity of the marine
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E-mail: mtscotti@ccae.ufpb.br (M.T. Scotti).
http://dx.doi.org/10.1016/j.bjp.2015.08.005
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editoraenvironment and its associated chemical diversity constitute
a practically unlimited resource of new active substances that
may  potentially be developed into novel bioactive products
(Souza et al., 2009a,b). The exploration of this biodiversity to
identify new chemical compounds has only just begun. Marine
organisms synthesize a plethora of small molecules with fas-
cinating chemical structures and potent biological properties.
The variety of marine organisms that have been discovered
to date offers a dramatic potential pool of resources for drug
discovery, and many new discoveries remain to be made (Bidon-
Chanal et al., 2013; Schumacher et al., 2011; Gerwick and Moore,
2012).
Natural marine products play an important role in increasing
the quality of life for patients with neurological diseases. These
products include fatty acids (such as n-3 fatty acid, which delays
the onset of AD), terpenes, alkaloids and varying other secondary
metabolites, all of which act through different pathways (Choi et al.,
2007; Gul and Hamann, 2005).
Several phlorotannins, such as eckstolonol [639514-05-9] (1),
eckol [99798-74-7] (2) and phlorofucofuroeckol-A [128129-56-6]
 Ltda. All rights reserved.
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3), may  represent useful nutraceuticals for the prevention of
D due to their inhibitory activities against acetylcholinesterase
AChE) and butylcholinesterase (BChE), which have been demon-
trated in vitro (Thomas and Kim, 2011; Yoon et al., 2009). Hexane
xtracts of Tetraselmis chuii, Chlorella minutissima and Rhodomonas
alina also exhibited cholinesterase inhibitory activity toward
ChE (Custódio et al., 2012). Additional kinase inhibitors that
re useful for the treatment of AD include steroidal alkaloid
-acetoxy-plakinamine B [1003045-50-8] (4) (Langjae et al.,
007), sargaquinoic acid [70363-87-0] (5) and sargachromenol
70363-89-2]; the latter two are meroditerpenes (6) (Choi et al.,
007). Sargaquinoic acid was found to potently inhibit BChE, a
ovel target for the treatment of AD, with potency comparable to
r greater than the anticholinesterases that are in current clinical
se (Mayer et al., 2011). Potential AChE inhibitors have been
iscovered in extracts from Latrunculia lendenfeldi and Latrunculia
ocagei sponges (Turk et al., 2013).
6
5
3
1 2
4
Additional studies have reported discoveries of novel glycogen
ynthase kinase 3 (GSK-3) inhibitors in natural marine products
Jin et al., 2006). Examples of these active marine-derived com-
ounds include palinurim [71947-64-3] (7) (Bidon-Chanal et al.,
013), lamellarin E [115982-19-9] (8) (Baunbaek et al., 2008),
ymenialdisine [82005-12-7] (9) (Meijer et al., 2000), merid-
anine E [213473-03-1] (10) (Radwan and El-Sherbiny, 2007),
anzamine A [104196-68-1] (11) (Hamann et al., 2007) and 6-
romoindirubin [200273-66-1] (12) (Meijer et al., 2003). Palinurin,
 furanosesquiterpene, inhibits GSK-3 activity through a novel
echanism of action (Bidon-Chanal et al., 2013). Debdab and col-
aborators have also reported the kinase inhibitory activities of
erivatives of the marine alkaloid leucettamine B [147395-96-8]
13) (Debdab et al., 2010).armacognosia 25 (2015) 690–697 691
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Tumescenamide A [1335094-05-7] (14) induces reporter gene
expression under the control of the insulin-degrading enzyme (IDE)
promoter, which suggests that it may  have promise as a potential
treatment for AD (Motohashi et al., 2010). The 3,5-dibromo-4-
methoxyphenyl-pyruvic acid [1356930-31-8] (15), isolated from
sponge Callyspongia sp., is able to modulate apolipoprotein E
(ApoE) (Tian et al., 2014). Dragmacidin D [142979-34-8] (16)
inhibits neural nitric oxide synthase, which may  prove to be
an option for the treatment of Huntington’s, Parkinson’s and
Alzheimer’s diseases (Yang et al., 2002).
14 15
16
Monoamine oxidase (MAO) is a FAD-containing enzyme that
catalyzes the oxidative deamination of a variety of biogenic and
xenobiotic amines including monoamine neurotransmitters such
as serotonin, noradrenaline and dopamine (Binda et al., 2011; Bolea
et al., 2013). MAO  plays an important role in the metabolism of
several neurotransmitters and could therefore be useful in the
treatment of a number of psychiatric and neurological diseases.
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AO  activity helps to ensure that neuron ﬁring rates through-
ut the body remain within homeostatic limits. MAO-B inhibitors,
uch as selegiline (R-(−)-deprenyl) [14611-52-0] (17) and rasagi-
ine [161735-79-1] (18), are useful compounds for the symptomatic
reatment of Parkinson’s and Alzheimer’s diseases (Zhu et al., 2008;
hoi and Choi, 2015), as they increase concentrations of synap-
ic dopamine by blocking its degradation (Fernandez and Chen,
007). Another MAO-B inhibitor, saﬁnamide [133865-89-1] (19), is
urrently undergoing phase III clinical trials as an adjuvant in com-
ination with a dopamine agonist or levodopa (Schapina, 2011).
AO-B inhibitors have also been extensively studied for their pos-
ible neuroprotective or disease-modifying actions, and there is an
bundant amount of evidence that MAO-B inhibitors have some
europrotective properties (Patil et al., 2013).
17 18 19
Caulerpin [26612-48-6] (20,  CLP 001) is a bisindole alkaloid
hat is primarily isolated from green algae of the genus Caulerpa
Souza et al., 2009a,b); it has an extra eight-member ring between
he two indole rings, which are incorporated directly with the
arbonyl group. Our research group has reported that caulerpin
as a non-selective spasmolytic effect and that this effect is due in
art to the inhibition of Ca2+ inﬂux through voltage-gated calcium
hannels (Cav) (Cavalcante-Silva et al., 2013) and noticed for the
rst time that caulerpin has showed a considerable antinociceptive
nd anti-inﬂammatory activities (Souza et al., 2009a,b).
20
OCH3
10
11
1
11'
10'
9' 8' 2'
1' 7a'
3a'
3'
H3CO
O
N N
N H
O
Computer-aided drug design (CADD) has become an indispens-
ble tool to the pharmaceutical industry and academia over the
ast decade (Lill and Danielson, 2011) and has been employed dur-
ng various stages of the drug-design process. Initially, this method
ocuses on reducing the overall number of possible ligands; in the
ater stages, during lead-optimization, the emphasis shifts to reduc-
ng experimental costs and the duration of time required to make
 discovery. Applied ligand-based virtual screening using Volsurf
nd Molegro descriptors and a random forest algorithm (a method
f machine learning) were included in the structure-based virtual
creening.
Once AD evidence an activation of inﬂammatory pathways
Wyss-Coray and Rogers, 2012) and caulerpin present considerable
nti-inﬂammatory activity, in this study, we created a database of
aulerpin analogs and evaluated it with a ligand-based model that
ncluded molecular descriptors, as well as with a structure-based
pproach that included docking studies of monoamine oxidase B
MAO-B) inhibitors.armacognosia 25 (2015) 690–697
Materials and methods
Database
From the ChEMBL database, we  selected a diverse set of
1523 structures (https://www.ebi.ac.uk/chembl/), which had been
screened (in vitro) to inhibit the single protein of human
monoamine oxidase B (Supporting Information Table S1). The com-
pounds were classiﬁed using values of -logIC50 (mol/l) = pIC50,
which led us to assign 696 actives (IC50 ≥ 6) and 827 in-actives
(IC50 < 6). In this case, IC50 represented the concentration required
for 50% inhibition of the single protein of human MAO-B. The
database that included caulerpin (CLP001) and its 108 analogs
(CLP002-109) was selected to build in our database. For all struc-
tures, SMILES codes were used as input data in a Marvin 14.9.1.0,
2014, ChemAxon (http://www.chemaxon.com). We used Stan-
dardizer software [JChem 14.9.1.0, 2014; ChemAxon (http://www.
chemaxon.com)] to canonize structures, add hydrogens, perform
aromatic form conversions, clean the molecular graph in three
dimensions, and save compounds in sdf format (Imre et al., 2003).
Volsurf descriptors
Three-dimensional structures (3D) were used as input data
in the Volsurf+ program v. 1.0.7 (Cruciani et al., 2000) and
were subjected to molecular interaction ﬁelds (MIF) (Cruciani
et al., 2000) to generate descriptors using the following probes:
N1 (amide nitrogen-hydrogen bond donor probe), O (carbonyl
oxygen-hydrogen bond acceptor probe), OH2 (water probe), and
DRY (hydrophobic probe). Additional non-MIF-derived descriptors
were generated to create a total of 128 descriptors (Cruciani et al.,
2000). Volsurf descriptors have been previously used to predict the
inhibitory actions of ﬂavonoids against enzymes (Scotti et al., 2011).
Drug-like score
Structures were used as input data in DRAGON Professional
version 6.0.30 to generate Dragon drug-like consensus, which was
calculated as a mean of 7 drug-like scores that were based on the
following: Lipinski’s rules (Lipinski et al., 2001); the drug-like ﬁlter
produced by Oprea et al. (2000); the drug-like score implemented
by Walters (Walters and Murcko, 2002); the drug-like ﬁlter pro-
duced by Chen (Chen et al., 2005); the drug-like score that was
based on two  rules proposed by Zheng (Zheng et al., 2005); the
drug-like score that was  proposed by Rishton (Rishton, 2003); and
the drug-like ﬁlter implemented by Veber and co-workers (Veber
et al., 2002).
Models
Knime 2.10.0 software (KNIME 2.10.0 the Konstanz Informa-
tion Miner Copyright, 2003–2014, www.knime.org) (Berthold et al.,
2007) was used to perform all of the following analyses. The
descriptors and class variables were imported from the Volsurf+
program, v. 1.0.7, and the data were divided using the “Partition-
ing” node with the “stratiﬁed sample” option to create a training
set and a test set, encompassing 80% and 20% of the compounds,
respectively. Although the compounds were selected randomly, the
same proportion of active and inactive samples was  maintained
in both sets. For internal validation, we  employed cross-validation
using ten randomly selected, stratiﬁed groups, and the distributions
according to activity class variables was  found to be maintained
in all validation groups and in the training set. Descriptors were
selected, and a model was generated using the training set and the
Random Forest algorithm (RF) (Breiman, 2001), using the WEKA
nodes (Hall et al., 2009). The parameters selected for RF included the
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Table  1
Summary of training, internal cross-validation, test results, and corresponding match results, which were obtained using the RF algorithm on the total set of 1523 compounds
(1218 were in the training set and 305 in the test set).
Training Validation Test
Samples Match %Match Match %Match Samples Match %Match
Active 557 556 99.8 393 70.6 139 115 82.7
Inactive 661 659 99.7 662 74.5 166 142 85.5
Overall 1218 1215 99.8 886 72.7 305 257 84.3
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Fig. 1. Receiver Operating Characteristic (ROC) plot, sensitivity versus 1-speciﬁcity,ollowing settings: number of trees to build = 50, seed for random
umber generator = 1, for training and internal cross-validation
ets. The internal and external performances of the selected mod-
ls were analyzed for sensitivity (true positive rate, i.e.,  active
ate), speciﬁcity (true negative rate, i.e.,  inactive rate), and accuracy
overall predictability). Additionally, the sensitivity and speciﬁcity
f the Receiver Operating Characteristic (ROC) curve was ﬁnd to
escribe true performance with more clarity than accuracy. The
lotted ROC curve shows the true positive (active) rate either ver-
us the false positive rates, i.e.  sensitivity versus (1-speciﬁcity). In
 two-class classiﬁcation, when a variable that is being investi-
ated cannot be distinguished between the two groups (i.e., when
here is no difference between the two distributions), the area
nder the ROC curve equals 0.5, which is to say that the ROC
urve will coincide with the diagonal. When there is a perfect
eparation of values between two groups (i.e., no overlapping of
istributions), the area under the ROC curve equals 1, which is
o say that the ROC curve will reach the upper left corner of the
lot (Hanley and McNeil, 1982). Additionally, we  calculated the
athews correlation coefﬁcient, wherein a value of 1 represents a
erfect prediction, a value of 0 represents a random prediction, and
 value of −1 represents total disagreement between prediction and
bservation.
ocking
The structure of MAO-B in complex with rosiglitazone (PDB ID
A7A) (Binda et al., 2012) was downloaded from the Protein Data
ank (http://www.rcsb.org/pdb/home/home.do). Alkaloid struc-
ures were submitted to molecular docking using the Molegro
irtual Docker, v. 6.0.1 (MVD) (Thomsen and Christensen, 2006).
ll of the water compounds were deleted from the enzyme struc-
ure, and the enzyme and compound structures were prepared
sing the same default parameter settings in the same software
ackage (Score function: MolDock Score; Ligand evaluation: Inter-
al ES, Internal HBond, Sp2–Sp2 Torsions, all checked; Number
f runs: 10 runs; Algorithm: MolDock SE; Maximum Interactions:
500; Max. population size: 50; Max. steps: 300; Neighbor distance
actor: 1.00; Max. number of poses returned: 5). The docking pro-
edure was performed using a GRID of 15 A˚ in radius and 0.30 in
esolution to cover the ligand-biding site of the MAO-B structure.
emplates with features expected to be relevant for ligand binding
rosiglitazone) were generated to perform docking. The Moldock
core [GRID] algorithm was used as the score function, and the
oldock search algorithm was used (Thomsen and Christensen,
006).
esults and discussion
The Volsurf (v 1.0.7) program generated 128 descriptors that,
ogether with the dependent variables (binary classiﬁcation) that
escribed whether the compounds were active (A) or inactive (I),
ere used as input data in the Knime program (v. 2.10.0) to generate
he Random Forest model. For all 1523 compounds that comprisedgenerated by the selected Random Forest model for test set and value of the area
under the curve (AUC).
the training data sets, the generation of all 128 descriptors by
Volsurf+ took approximately 20 min using a computer with an i7
processor, running at 3.4 GHz, and equipped with 12 GB of RAM
memory.
Table 1 summarizes the statistical indices of the RF model for
the training, cross-validation, and test sets. For the training set,
the learning machine program gave similar hit rates for the inac-
tive compounds and active compounds, which were above 99.7%.
However, for the cross-validation and test sets, the RF model was
better at predicting the inactive compounds; therefore, the speci-
ﬁcity (true negative rate) was higher for the cross-validation and
test sets (74.5% and 85.5%, respectively) than the sensitivity (true
positive rate), which was  measured to be 70.6% and 82.7%, respec-
tively (Table 1). Because the false positive rate (1-speciﬁcity) was
signiﬁcantly lower, there was  only 25.5% and 14.5% speciﬁcity for
the cross-validation and test sets (Table 1), respectively. Therefore,
compounds selected by the model as active had a low probabil-
ity of being false positives (i.e., of being inactive). These results are
illustrated in Table 1 as well as in the ROC (Receiver Operating Char-
acteristic) plot that was  generated for the test set, which plotted the
true positive (active) rate against the false positive rates and had an
area under the curve value of approximately 0.846 (Fig. 1), which
is close to 1.
The Matthews Correlation Coefﬁcient (MCC) values for the
training, cross-validation and test sets were 0.99, 0.46 and 0.68,
respectively. Because an MCC  value of 1 represents a perfect
prediction, a value of 0 represents a random prediction, and a
value of −1 indicates total disagreement between prediction and
observation, the RF model indicated that the values of MCC  that
were calculated were signiﬁcant, particularly with respect to the
training and test sets. The equation used to obtain these values is
as follows:
MCC  = TP × TN − FP × FN√
(TP + FP)(TP + FN)(TN + FP)(TN+FN)
,where TP = true positive rate, TN = true negative rate, FP = false pos-
itive rate, and FN = False negative rate.
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Docking was validated redocking the original ligand rosiglita-
one in active site of MAO-B as observed in crystallography pdb ﬁle
PDB ID 4A7A) (Binda et al., 2012). The same parameter describes
o evaluate caulerpin and analogs was used in validation. Super-
osition of poses is represented in Fig. 2 and shows a perfect
atch.
Initially, we sought to evaluate the potential of using caulerpin
s an MAO-B inhibitor. The results presented in Table 2 indi-
ate that caulerpin exhibits potential inhibitory activity and can
herefore be used as a lead. As we aimed to include a restric-
ive screening in this study, we selected 33 as the perceptual
imit for our docking methodology, such that only the analogs
hat had energy lower than a −151.87 Moldock score (i.e., the
owest 33% of MolDock energies of the whole database) were
elected as active. The Volsurf program (v. 1.0.7) generated 128
escriptors that, together with a dependent variable (binary classi-
cation), described whether a compound was active (A) or inactive
I); these were used as input data in the Knime software pro-
ram (v. 2.10.0). From the RF model, we selected the compounds
lassiﬁed as being active (i.e., having a predicted probability of
reater than 50%). Crossing the results, we observed a consensus of
6.9% between the methodologies. Using the mixed ligand-based
nd structure-based approach, we selected nine active analogs of
aulerpin (21).
21In analyzing the ﬁve best analogs from each methodological
pproach, we observed a clear connection between the values
btained for the compounds CLP 012, CLP 068, CLP 078 and CLP
00, which were the lead results in the two studies. In evaluatingking pose (gray) validating the methodology.
the chemical characteristics from the active analogs, we observed
that a monosubstitution that was symmetrical with chlorine and
methyl at positions 4 and 4′ and 5 and 5′, respectively, was not
signiﬁcantly changed compared to caulerpin (21). However, the
presence of an amide or acyl halide polar group in R and a short
nonpolar allyl or butyl chain in R1 generated lower docking ener-
gies and higher predicted probability. All active analogs exhibited
favorable values in the dragon consensus of their drug-like scores
(the consensus is calculated as the mean of the results of seven
drug-like scores). With the exception of CLP109, all active analogs
presented scores above 0.75 (Table 2), highlighting the promising
scores of the leading analogs (CLP 012, CLP 068, CLP 078 and CLP
100), which had scores above 0.80. A drug-like score is a value rang-
ing from 0 to 1, in which a value of 1 indicates that a compound is
a potential drug candidate.
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Table  2
Summary of the Moldock energy, predicted probability (%) and Dragon drug-like consensus of both caulerpin (CLP001) and of its analogs that were found to be active against
MAO-B.
Moldock energy Predicted probability Drug-like score
CLP001 −152 58 0.77
CLP012 −164 60 0.87
CLP032 −153 64 0.75
CLP049 −155 52 0.87
CLP068 −159 66 0.87
CLP078 −155 62 0.80
CLP100 −161 64 0.87
CLP107 −152 58 0.77
CLP108 −155 58 0.75
CLP109 −153 54 0.65
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a possibility of how they can produce inhibitory effects againstIn corroborating the analysis of active compounds, several
imilar characteristics to the inactive group were observed,
ncluding the presence of groups with similar polarities in R
r R1 (21). Whether in a symmetric (CLP 006 and CLP 009)
r asymmetric (CLP 0013) context, the presence of a polar
roup was found to negatively inﬂuence performance. The same
ffect occurs in the presence of nonpolar groups (CLP 037 and
LP 074). The substitution of both indole nitrogens with alter-
ative heteroatoms such as oxygen to serve as the binding
roups of that position reduced the inhibitor effect (CLP 065 and
LP 022).Although aromatic substitutions did not lead CLP 032 and
CLP 049 to become more effective, both a change in position
and disubstitution were found to signiﬁcantly reduce potency
(CLP 029, CLP 051, CLP 033 and CLP 057). Strong activators
such as hydroxyl also decreased inhibitor activity (CLP 034 and
CLP 036).
In Fig. 3, it is possible to observe the hydrogen bonding (H-bond)
interactions between rosiglitazone (A), the drug utilized as tem-
plate, and two caulerpin analogs, which were classiﬁed as active
(CLP 012) (B) and inactive (CLP 006) (C). It is also possible to observe
the interactions between the Tyr 435 (A) residue from MAO-B and
rosiglitazone (A), and between Tyr 435(A) and CLP 012 (B). In CLP
012 (D) and CLP 006 (E), the electrostatic distribution is shown,
corroborating the importance of polar (blue) and non-polar (green)
substitutions to activity.
In this work, we identiﬁed the fundamental physical and
chemical characteristics of caulerpin analogs (21) and indicatedMAO-B. Ligand and structure-based results, associated with drug-
like score, allow us to indicate the potential possibility of using this
skeleton as a tool against AD in future studies.
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Big. 3. Hydrogen bonding interactions of rosiglitazone (A), CLP 012 (B) and CLP 006
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